Retrophin Inc (NASDAQ:RTRX) Director Steve Aselage sold 10,000 shares of Retrophin stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $20.00, for a total transaction of $200,000.00. Following the completion of the transaction, the director now directly owns 238,732 shares of the company’s stock, valued at $4,774,640. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Steve Aselage also recently made the following trade(s):

  • On Thursday, May 14th, Steve Aselage sold 3,062 shares of Retrophin stock. The shares were sold at an average price of $15.09, for a total transaction of $46,205.58.
  • On Tuesday, May 12th, Steve Aselage sold 1,000 shares of Retrophin stock. The shares were sold at an average price of $17.16, for a total transaction of $17,160.00.

Shares of Retrophin stock traded up $0.17 during trading on Monday, reaching $19.73. The company’s stock had a trading volume of 505,375 shares, compared to its average volume of 464,282. The business’s 50-day moving average price is $16.23 and its 200-day moving average price is $15.33. The firm has a market cap of $844.12 million, a PE ratio of -8.05 and a beta of 0.81. Retrophin Inc has a 52 week low of $8.98 and a 52 week high of $21.95. The company has a quick ratio of 5.88, a current ratio of 5.97 and a debt-to-equity ratio of 0.92.

Retrophin (NASDAQ:RTRX) last announced its earnings results on Monday, May 11th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.68) by $0.70. The company had revenue of $47.77 million during the quarter, compared to analysts’ expectations of $43.14 million. Retrophin had a negative net margin of 57.01% and a negative return on equity of 43.15%. Equities analysts predict that Retrophin Inc will post -1.56 earnings per share for the current year.

A number of brokerages have recently weighed in on RTRX. Zacks Investment Research raised shares of Retrophin from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a research note on Monday, May 4th. BTIG Research assumed coverage on shares of Retrophin in a research report on Tuesday, June 16th. They issued a “buy” rating and a $25.00 target price for the company. BMO Capital Markets upped their target price on shares of Retrophin from $33.00 to $34.00 and gave the company an “outperform” rating in a research note on Tuesday, May 12th. BidaskClub upgraded shares of Retrophin from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Canaccord Genuity reiterated a “buy” rating and set a $26.00 target price on shares of Retrophin in a research report on Tuesday, May 19th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Retrophin presently has an average rating of “Buy” and a consensus target price of $26.50.

A number of hedge funds have recently bought and sold shares of the stock. AXA raised its stake in Retrophin by 19.3% in the first quarter. AXA now owns 197,400 shares of the biopharmaceutical company’s stock valued at $2,880,000 after purchasing an additional 32,000 shares in the last quarter. Invesco Ltd. raised its stake in Retrophin by 54.0% in the first quarter. Invesco Ltd. now owns 26,646 shares of the biopharmaceutical company’s stock valued at $389,000 after purchasing an additional 9,349 shares in the last quarter. Atom Investors LP raised its stake in Retrophin by 26.8% in the first quarter. Atom Investors LP now owns 190,136 shares of the biopharmaceutical company’s stock valued at $2,774,000 after purchasing an additional 40,135 shares in the last quarter. Janus Henderson Group PLC acquired a new position in Retrophin in the first quarter valued at about $2,322,000. Finally, Massachusetts Financial Services Co. MA raised its stake in Retrophin by 18.8% in the first quarter. Massachusetts Financial Services Co. MA now owns 88,425 shares of the biopharmaceutical company’s stock valued at $1,290,000 after purchasing an additional 13,995 shares in the last quarter.

Retrophin Company Profile

Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

See Also: What is the Current Ratio?

Insider Buying and Selling by Quarter for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.